ArticleScientific reports2025
Daidzin improves the cisplatin chemosensitivity for osteosarcoma via binding to β-catenin protein and suppressing the wnt pathway.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Osteosarcoma (OS) mainly occurs in adolescents and children, accompanied with chemotherapy resistance as well as unsatisfactory treatment outcome. Recent studies have discovered a series of natural products with anticancer activity, which have important translational value. Daidzin has been reported with a variety of biological activities. We aim to explore whether daidzin has therapeutic potential for OS. In this study, cell based and in vivo studies showed that daidzin can inhibit the ability of OS cells to proliferate and metastasize. Compared to single treatment arms, combined treatment of daidzin and cisplatin, a classic recommendation for OS treatment, showed a further suppression in OS cell viability, migration and invasion ability, and led to further apoptosis. Mechanistically, daidzin was found to downregulate the β-catenin expression and further inhibited the Wnt pathway. However, daidzin did not alter the transcriptional level of β-catenin. Molecular docking showed a potential interaction between daidzin and β-catenin protein, and their combination was further confirmed by thermal shift assay and MST assay. Daidzin was found to reduced protein stability of β-catenin, and only transfection of β-catenin mutant (a mutant that targets the binding sites to daidzin) at the same time as daidzin treatment could effectively attenuate the antitumor effect of daidzin. Our study suggests that daidzin has translational value as a potential adjuvant to improve treatment outcomes for OS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.